Synpromics joined the BSGCT in Sheffield at the end of June to share the latest progress in gene and cell therapy. The Annual Meeting kicked off to a great start with a welcome networking reception, sponsored by Synpromics, held in the beautiful Winter Garden. This provided an excellent opportunity to catch up with current and possible future collaborators.
The Synpromics team at the BSGCT Annual Meeting
Edinburgh, UK, 16th May 2019 / Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals.
On the first day, CSO Michael Roberts presented to a packed room as part of the Tools & Technologies Forum. It was standing room only during his presentation: Mastering Gene Control to Enable the Next Generation of Gene Medicines.
David Venables presented to a full room of investors at the ARM Cell & Gene Therapy Investor Day in New York. Watch David's presentation below or view the pdf here.
Edinburgh, UK, 5th December 2018 / Synpromics is pleased to hear that its partner, uniQure (NASDAQ:QURE), has announced the incorporation of its promoter, developed by Synpromics, in a new preclinical research target. This follows recent positive data, presented at the ESGCT world congress, demonstrating that this highly selective liver promoter is at least eight times more potent than the current industry standard.
